Management approaches for dry eye disease (DED) typically start with low-risk, easily accessible, patient-applied therapies like artificial tears for early-stage disease. As the condition worsens, treatment progresses to more advanced therapies for severe forms of DED. This study aims to compare the effectiveness and safety of pilocarpine as a secretagogue versus artificial tears in the treatment of dry eye disease. Our goal is to provide reliable, high-quality evidence regarding the efficacy of secretagogues, thereby contributing to the development of recommendations that aid clinicians in their decision-making process
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Pilocarpine is a muscarinic agonist
artificial tears used for the treatment of Dry eye
Al-Azhar university
Damietta, Egypt
Ocular Surface Disease Index
Time frame: At the baseline and after 6 weeks
tear film break-up time
Time frame: At the baseline and after 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.